1. Home
  2. HOWL vs IKNA Comparison

HOWL vs IKNA Comparison

Compare HOWL & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • IKNA
  • Stock Information
  • Founded
  • HOWL 2017
  • IKNA 2016
  • Country
  • HOWL United States
  • IKNA United States
  • Employees
  • HOWL N/A
  • IKNA N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • IKNA Health Care
  • Exchange
  • HOWL Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • HOWL 87.4M
  • IKNA 81.6M
  • IPO Year
  • HOWL 2021
  • IKNA 2021
  • Fundamental
  • Price
  • HOWL $1.49
  • IKNA $1.49
  • Analyst Decision
  • HOWL Strong Buy
  • IKNA Buy
  • Analyst Count
  • HOWL 2
  • IKNA 2
  • Target Price
  • HOWL $9.50
  • IKNA $3.00
  • AVG Volume (30 Days)
  • HOWL 260.9K
  • IKNA 169.0K
  • Earning Date
  • HOWL 03-06-2025
  • IKNA 03-11-2025
  • Dividend Yield
  • HOWL N/A
  • IKNA N/A
  • EPS Growth
  • HOWL N/A
  • IKNA N/A
  • EPS
  • HOWL N/A
  • IKNA N/A
  • Revenue
  • HOWL $3,386,000.00
  • IKNA $659,000.00
  • Revenue This Year
  • HOWL N/A
  • IKNA N/A
  • Revenue Next Year
  • HOWL $34.17
  • IKNA N/A
  • P/E Ratio
  • HOWL N/A
  • IKNA N/A
  • Revenue Growth
  • HOWL N/A
  • IKNA N/A
  • 52 Week Low
  • HOWL $1.26
  • IKNA $1.22
  • 52 Week High
  • HOWL $8.19
  • IKNA $1.94
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 54.09
  • IKNA 48.35
  • Support Level
  • HOWL $1.28
  • IKNA $1.40
  • Resistance Level
  • HOWL $1.60
  • IKNA $1.60
  • Average True Range (ATR)
  • HOWL 0.10
  • IKNA 0.07
  • MACD
  • HOWL 0.03
  • IKNA 0.01
  • Stochastic Oscillator
  • HOWL 67.65
  • IKNA 47.62

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: